je.st
news
Tag: multiple
Keysight Technologies' PXI VNA Wins Multiple Industry Awards Selected as One of the Most Significant Products of 2014
2015-01-19 11:30:51| Industrial Newsroom - All News for Today
SANTA ROSA, Calif. Keysight Technologies, Inc. (NYSE: KEYS) today announced that it has received three awards for its recently introduced M937XA PXI Vector Network Analyzer. The awards include 1) Product of the Year from Electronic Products magazine, 2) Top Products of the Year 2014 from Microwave and RF magazine...
Tags: of
products
industry
selected
PTC's ThingWorx And Axeda Internet Of Things (IoT) Enabling Technologies Win Multiple Excellence Awards At CES 2015
2015-01-19 03:47:47| electronicsweb Home Page
PTC recently announced that the Internet of Things (IoT) enabling technology businesses it acquired in 2014 – ThingWorx and Axeda –received several prestigious awards from Compass Intelligence at last week’s International CES, the world’s largest consumer electronics show
Tags: internet
things
multiple
win
Trade News: Keysight Technologies' Pxi Vna Wins Multiple Industry Awards
2015-01-14 20:55:54| Auto Parts - Topix.net
Keysight Technologies, Inc. today announced that it has received three awards for its recently introduced M937XA PXI Vector Network Analyzer . The awards include 1) Product of the Year from Electronic Products magazine, 2) Top Products of the Year 2014 from Microwave and RF magazine, and 3) Hot 100 Products of 2014: Test & Measurement from EDN.
Tags: news
industry
multiple
trade
Lilly, Merck Enter Collaboration Agreement to Research Immuno-Oncology Combination Regimens in Multiple Types of Cancer
2015-01-13 14:00:00| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. & INDIANAPOLIS Combinations of KEYTRUDA (pembrolizumab) with Alimta (pemetrexed), Cyramza (ramucirumab), or necitumumab to be explored KENILWORTH, N.J. & INDIANAPOLIS--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the US and Canada, and Eli Lilly and Company (NYSE:LLY) announced today an oncology clinical trial collaboration to evaluate the safety, tolerability and efficacy of KEYTRUDA (pembrolizumab), Mercks anti-PD-1 therapy, in combination with Lilly compounds in multiple clinical trials: Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Claire Mulhearn, 908-236-1118orInvestors:Justin Holko, 908-740-1879orLillyEli Lilly and CompanyKeri McGrath, 317-277-3768Communications Managermcgrath_happeks@lilly.com Ticker Slug: Ticker: MRK Exchange: NYSE Ticker: LLY Exchange: NYSE read more
Tags: enter
research
agreement
types
Visteon to Unveil Advanced Connectivity Solutions in Multiple Vehicles at 2015 International CES
2015-01-07 11:30:54| Industrial Newsroom - All News for Today
Global Automotive Supplier Creates Value in Vehicles for Automakers, Dealers and Consumers LAS VEGAS - Visteon Corporation (NYSE: VC) will showcase advanced technology in three different passenger cars to demonstrate how it can increase a vehicle's value throughout its lifecycle by reducing warranty costs and...
Tags: international
advanced
multiple
solutions
Sites : [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] next »